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Abstract. The aim of this study was to characterize the infection by respiratory syncytial virus (RSV), identify risk factors,
complications and compare treatment strategies in children admitted to two Portuguese hospitals. It was a retrospective study
performed between January 2005 and December 2006. Demographic and socioeconomic data, risk factors, treatment, compli-
cations and medical follow-up were analyzed. A total of 328 children were studied (135 from Hospital Dona Estefˆania and
193 from Hospital Fernando Fonseca), about half (52.7%) being male, with a mean age of 5 months. 41% of the patients
were from a poor socioeconomic context, 55.8% had older siblings, 32.2% had smoking parents and 11.3% had reactive airway
disease. Complications occurred in 76.1% of the patients, namely, hypoxemia (63.5%), secondary bacterial infection (26.5%),
atelectasis (11.5%), respiratory failure (10%) and apnea (2.4%). Most of the patients (92.3%) were treated with bronchodilators,
69% had oxygen supplementation, 45% were on antibiotics and 31% were treated with systemic corticosteroids. Ten percent
needed mechanical ventilation. Twenty-seven (8.2%) children developed reactive airway disease. Having older siblings (63.1%
vs. 49.3% P = 0.05) and being newborn (32.7% vs. 16.5% P = 0.006) resulted as risk factors for complications, while the
risk factors identified for bacterial infection were having older siblings (71.4% vs. 55.7%; P = 0.013) and being from a poor
socioeconomic context (64.7% vs. 47.6%; P = 0.017). The treatment strategies differed in the two hospitals (Hospital Fernando
Fonseca vs. Hospital Dona Estefaˆnia) regarding the use of systemic corticosteroids (1.6% vs. 73.3%, P = 0.000) and antibiotics
(39.4% vs. 52.6%; P = 0.011). RSV infections can result in serious complications. According to the current knowledge, most of
the therapeutic measures carried out in this study were probably unnecessary. It is important to establish clear national guidelines
for the treatment of RSV infection.
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1. Introduction
Respiratory syncytial virus (RSV) is the leading
cause of lower respiratory tract infections in the first
two years of life and is responsible for an important
number of hospital admissions (of young children).
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This pathogen is ubiquitous throughout the world and
causes seasonal outbreaks. In temperate climates, late
fall and wintertime epidemics of bronchiolitis are usu-
ally associated to RSV infections. Severe disease is
characterized by progressive respiratory effort, apnea,
need for intravenous hydration, supplemental oxygen
or mechanical ventilation. Risk factors for severe RSV
disease are congenital heart disease, chronic lung con-
ditions, prematurity and age less than 6 weeks. These
factors in association with apnea during the acute phase,
pulmonaryconsolidation on chest x-ray and hypoxemia
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Table 1
Risk factors for respiratory syncytial virus infection in our population
Parameters Hospital Fernando Fonseca n (%) Hospital Dona Estefˆania n (%) Total n (%)
Prematurity 18 (9.3) 17 (12,6) 35 (10.6)
Daycare 21 (10.8) 25 (18.5) 46 (14)
Smoking parents 63 (32.6) 41 (30.7) 104 (32.2)
Older brothers 123 (63.7) 60 (44.4) 183 (55.8)
Asthma in family 34 (17.6) 46 (34) 80 (24.3)
Poor economic status 75 (38.8) 60 (44.4) 135 (41)
Congenital cardiopathy 3 (1.5) 6 (4.4) 9 (2.7)
Chronic pulmonary disease 2 (1) 1 (0.7) 3 (0.9)
Reactive airway disease 25 (12.9) 12 (8.8) 37 (11.3)
Immunodeficiency 0 (0) 2 (1.5) 2 (0.6)
on admission, are independently associated with length
of hospitalization for RSV [1,2]. Despite the com-
mon occurrence of RSV lower respiratory tract infec-
tions, there is a great deal of uncertainty regarding its
management. At the present time, there appears to be
no evidence supporting any therapy for acute bronchi-
olitis other than supportive measures such as oxygen
supplementation or intravenous feeding. In fact, the
use of bronchodilators, corticosteroids and ribavirin are
not supported by any of the systematic reviews pub-
lished [3–8].
The aim of this study was to characterize the infec-
tion by RSV, identify risk factors, complications and
compare treatment strategies in children admitted to a
pediatric hospital in the central area of Lisbon, Hospital
Dona Estefaˆnia, (HDE) and to a pediatric hospital in
a suburban area in the outskirts of Lisbon, Amadora-
Sintra, Hospital Fernando Fonseca (HFF).
2. Materials and methods
A retrospective study of children, under 36 months
of age, admitted with RSV infection between Jan-
uary 2005 and December 2006. Laboratory testing
for RSV was performed using an indirect immunofluo-
rescence test (Bartels VRK ) and a rapid chromatog-
raphy test of nasopharyngeal secretions (RSV Respi-
Strip ). Less than 1.5% of cases were diagnosed us-
ing serology (Euroimmun Elisa incubation: Anti-RSV
enzyme-linked immunosorbent assay (immunoglobu-
lin G) and anti-RSV enzyme-linked immunosorbent as-
say (immunoglobulin M ).
Demographic and socioeconomic data, risk factors,
treatment, complications, length of hospitalization,
medical treatment since discharge, medical follow-up
and hospitalization costs were analyzed. Hypoxemia
was defined as oxygen saturation below 94%. Bacteri-
al superinfection was considered when abnormal white
blood cell count ( 15.000 or 5000/mm 3), C-reactive
protein above 5 mg/dL, lobar consolidation on the chest
X-ray or acute otitis media were present. Recurrent
wheezing was defined as three or more episodes of
cough and shortness of breath with expiratory rhonchi
documented by a physician in the files. Immunodefi-
ciency, chronic neonatal lung disease, congenital heart
disease and recurrent wheezing were considered chron-
ic diseases. Statistical analysis was performed using
SPSS 11.0 for windows. Chi-square and Fisher’s
exact test were used to compare frequencies between
groups. Student’s t-test and Mann-WhitneyU rank sum
test were used to compare means or medians between
groups. P < 0.05 was considered significant.
3. Results
A total of 328 patients were included (135 from HDE
and 193 from HFF) with a mean age at admission of 5
months and median of 3 months (patients age ranged
from 9 days to 36 months). About half (52.7%) were
male and 72.3 % were white. 183 (55.8%) patients had
older siblings, 135 (41%) were from a poor socioeco-
nomic context, 104 (32.2%) had smoking parents, and
46 (14%) attended daycare. Eighty (24.3%) children
had a family history of asthma and 37 (11.3%) had reac-
tive airway disease. Amongst the 50 (15.2%) children
with chronic disease, three had chronic lung disease,
nine had congenital heart disease, two were immuno-
compromised and 37 patients had recurrent wheezing.
Thirty-five (10.6%) patients were born prematurely and
three had received palivizumab. (Table 1) There was
no statistically significant difference between hospitals
in respect to patients with chronic diseases. On admis-
sion the diagnosis was bronchiolitis in 285 (86.9%),
pneumonia in 34 (10.3%), laryngitis in five (1.5%) and
upper respiratory infection in four cases (1.2%).
Complications occurred in 249 cases (76.1%): hy-
poxemia (63.5%), bacterial infection (26.5%), atelecta-
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Fig. 1. Complications observed during hospitalization.
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Fig. 2. Treatment options used in children admitted with respiratory syncytial virus infection.
sis (11.5%) respiratory failure (10%) and apnea (2.4%).
The mortality rate was 0.9% (three children) and was
related to respiratory insufficiency (Fig. 1). Two chil-
dren were younger than 1-month-old. Risk factors for
complications were being newborn (32.7% vs. 16.5%,
P = 0.006), white race (84.8 % vs. 72.6%, P = 0.024)
and having older siblings (63.1% vs. 49.3%, P = 0.05).
Risk factors identified for developing bacterial super-
infection was having older siblings (71.4% vs. 55.7%,
P = 0.013) and being from a poor socioeconomic con-
text (64.7% vs. 47.6%, P = 0.017).
Therapeutics administered included bronchodilators
in 92.3%, oxygen in 69%, chest physiotherapy in
66.1%, antibiotics in 45%, systemic corticosteroids in
31%, and inhaled corticosteroids in 4.8%. Seventy-one
percent of children needed intravenous fluids and 10%
mechanical ventilation (Fig. 2). The newborn group
(87.9% vs. 22, 1%, P < 0.001, Odds ratio-25.542) and
the group of children under 6 months of age (97% vs.
62.6%, P < 0.001, Odds ratio-19.13) were at a high-
er risk for needing mechanical ventilation. None was
medicated with ribavirin.
The treatment strategies differed in the two hospitals
(HFF vs. HDE) regarding the use of systemic corticos-
teroids (1.6% vs. 73.3%, P = 0.000) and antibiotics
(39.4% vs. 52.6%; P = 0.011) (Table 2).
The mean length of hospital stay was 8.8 days (me-
dian of 8 days, with a minimum stay of 1 and a maxi-
mum of 78 days). There was no statistically significant
difference between hospitals with respect to length of
stay. Sixty-three patients (19%) needed intensive care
treatment.
After discharge, 169 (51.2%) children were pre-
scribed bronchodilators, 69 (21%) were on antibiotics,
48 (14.6%) had chest physiotherapy, 32 (9.7%) were
on systemic corticosteroids, and three (0.9%) needed
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Table 2
Comparison of treatment strategies between the two hospitals Hospital Fernando Fonseca and Hospital Dona
Estefaˆnia
Parameters Hospital Fernando Fonseca n (%) Hospital Dona Estefˆania n (%) P
Inhaled corticosteroids 10 (5.2) 6 (4.4) 0.679
Chest physiotherapy 135 (74.4) 82 (60.7) 0.007
Mechanical ventilation 21 (10.9) 12 (8.9) 0.587
Oxygen 127 (65.8) 99 (73.3) 0.319
Antibiotics 76 (39.4) 71 (52.6) 0.011
Systemic corticosteroids 3 (1.6) 99 (73.3) < 0.001
Bronchodilators 172 (90.1) 131 (97.8) 0.006
oxygen. Twenty-seven children (8.2%) developed re-
current wheezing. There was no statistically significant
difference between the two hospitals.
The cost of the hospitalization of the 328 children
was 573,370 Euro. The average cost per child was dif-
ferent in the two hospitals but not statistically signifi-
cant (2022 vs. 1546 Euro, P = 0.115).
4. Discussion
Our study provides an insight into the management
of acute RSV infection in two Lisbon hospitals. The
considerable differences between the management of
this disease in the two hospitals are comparable to those
observed between hospitals in other countries [1,3,9,
10]. A recent survey revealed that management of acute
bronchiolitis varies considerably between and within
countries and continents [1]. Those differences have
been found in the use of ventilation, intensive care, and
drugs such as bronchodilators, steroids, ribavirin and
antibiotics. Actually, studies performed in the United
States, Canada and Netherlands demonstrated that this
variation is related to hospital and individual prefer-
ences, rather than with patient severity or impact on
outcome [9,11]. In a small country such as ours, these
differences are quite striking. A statistically significant
difference in the characteristics of our population with
respect to chronic diseases was not found, so the most
likely explanation for this phenomenon is the lack of
a national consensus on the management of RSV in-
fection. In 2006, the American Academy of Pediatrics
published evidence-based guidelines for the Diagnosis
and Management of Bronchiolitis. These guidelines
address the diagnosis of bronchiolitis as well as var-
ious therapeutic interventions including bronchodila-
tors, corticosteroids, antibiotics, hydration, chest phys-
iotherapy, and oxygen. Recommendations are made
also for RSV infection [11]. These guidelines recom-
mend that bronchodilators, corticosteroids, chest phys-
iotherapy and antibiotics should not be used routinely
in the management of bronchiolitis. Our study shows
that practices in use at our hospitals differ from the cur-
rent guidelines. We think that new prospective multi-
centric studies are needed to study the impact of theses
guidelines on the management and outcome of children
hospitalized for RSV infection.
We found that newborns, white children and children
having older siblings had a higher risk of developing
complications. Except for newborns, these weren’t
traditional risk factors identified in other studies of RSV
infections [1,3,9,12–16], perhaps because they were
considered only factors of increased risk of acquiring
RSV disease.
We found a 26.5% rate of bacterial superinfection,
including children with the diagnosis of acute otitis me-
dia. Several retrospective studies identified lower rates
of serious bacterial infections (3.7%) [17–19], and oth-
ers reported about 53% of bacterial acute otitis media
in RSV infected children [20]. None reported the glob-
al incidence of bacterial superinfection. Leukocytosis,
increased C-reactive protein levels and lobar consoli-
dation on the chest X-ray are found in up to 30% of
infants with viral bronchiolitis and do not allow for
adequate identification of patients with bacterial infec-
tion [9]. According to this, the incidence of secondary
bacterial infection may be overestimated in the present
study. Forty-five percent of our population was treated
with antibiotics and only 26.5% had supposed bacteri-
al infection. Concomitant serious bacterial infections
are rare in infants and children hospitalized with RSV
lower respiratory tract infections. The empiric use of
broad-spectrum intravenous antibiotics is unnecessary
in children with typical signs and symptoms of RSV
lower respiratory tract infection [21].
Our data identified that having older siblings and
coming from a poor socioeconomic context are risk
factors for developing bacterial infection in the course
of the disease. Nevertheless, prospective studies are
needed, to support measures of prevention and the man-
agement of these situations.
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Consistent with data published in previous studies [1,
9] the mortality rate was below 1% and occurred in
children less than 3 months of age.
The average days of hospital stay was eight in our
population, similar to data published on Canadian RSV
patients [9] and in studies among Continental Eu-
rope [1]. In the US, Australia and UK the average days
of hospitalization was four. These differences are prob-
ably related to different discharge criteria and not to a
higher proportion of severely ill cases, as suggested by
other studies [1].
References
[1] C.E. Behrendt, M.D. Decker, D.J. Burch and P.H. Watson,
International variation in the management of infants hospital-
ized with respiratory syncytial virus. International RSV Study
Group, Eur J Pediatr 15 (1998), 215–220.
[2] S. Unger and S. Cunningham, Effect of oxygen supplementa-
tion on length of stay for infants hospitalized with acute viral
bronchiolitis, Pediatrics 121 (2008), 470–475.
[3] P.L. Brand and A.A. Vaessen-Verberne, Differences in man-
agement of ronchiolitis between hospitals in The Nether-
lands. Dutch Paediatric Respiratory Society, Eur J Pediatr 159
(2000), 343–347.
[4] M.M. Garrison, D.A. Christakis, E. Harvey, P. Cummings and
R.L. Davis, Systemic corticosteroids in infant bronchiolitis:
A meta-analysis, Pediatrics 105 (2000), E44.
[5] W.C. Bordley, M. Viswanathan, V.J. King et al., Diagnosis
and testing in bronchiolitis: a systematic review, Arch Pediatr
Adolesc Med 158 (2004), 119–126.
[6] H. Patel, R.W. Platt, G.S. Pekeles and F.M. Ducharme, A
randomized, controlled trial of the effectiveness of nebulized
therapy with epinephrine compared with albuterol and saline
in infants hospitalized for acute viral bronchiolitis, J Pediatr
141 (2002), 818–824.
[7] L. Hartling, N. Wiebe, K. Russell, H. Patel and T.P. Klassen,
Epinephrine for bronchiolitis, Cochrane Database Syst Rev 1
(2004), CD003123.
[8] H. Patel, R. Platt, J.M. Lozano and E.E. Wang, Glucocorticoids
for acute viral bronchiolitis in infants and young children,
Cochrane Database Syst Rev 3 (2004), CD004878.
[9] E.E. Wang, B.J. Law, F.D. Boucher et al., Pediatric In-
vestigators Collaborative Network on Infections in Canada
(PICNIC) study of admission and management variation in
patients hospitalized with respiratory syncytial viral lower res-
piratory tract infectionm, J Pediatr 129 (1996), 390–395.
[10] D.A. Christakis, C.A. Cowan, M.M. Garrison, R. Molteni, E.
Marcuse and D.M. Zerr, Variation in inpatient diagnostic test-
ing and management of bronchiolitis, Pediatrics 115 (2005),
878–884.
[11] Diagnosis and management of bronchiolitis. American Acade-
my of Pediatrics Subcommittee on Diagnosis and Manage-
ment of Bronchiolitis, Pediatrics 118 (2006), 1774–1793.
[12] K.N. Carroll, T. Gebretsadik, M.R. Griffin et al., Increasing
burden and risk factors for bronchiolitis-related medical vis-
its in infants enrolled in a state health care insurance plan,
Pediatrics 122 (2008), 58–64.
[13] G. Corsello, P. Di Carlo, L. Salsa et al., Respiratory syncytial
virus infection in a Sicilian pediatric population: risk factors,
epidemiology, and severity, Allergy Asthma Proc 29 (2008),
205–210.
[14] C.B. Hall, G.A. Weinberg, M.K. Iwane et al., The burden of
respiratory syncytial virus infection in young children, N Engl
J Med 360 (2009), 588–598.
[15] M. Lanari, M. Giovannini, L. Giuffre´ et al., Prevalence of res-
piratory syncytial virus infection in Italian infants hospitalized
for acute lower respiratory tract infections, and association
between respiratory syncytial virus infection risk factors and
disease severity, Pediatr Pulmonol 33 (2002), 458–465.
[16] G.A. Rossi, M.C. Medici, M.C. Arcangeletti et al., Risk factors
for severe RSV-induced lower respiratory tract infection over
four consecutive epidemics, Eur J Pediatr 166 (2007), 1267–
1272.
[17] S. Leader and K. Kohlhase, Recent trends in severe respiratory
syncytial virus (RSV) among US infants, 1997 to 2000, J
Pediatr 143 (2003), 127–132.
[18] K. Purcell and J. Fergie, Lack of usefulness of an abnormal
white blood cell count for predicting a concurrent serious bac-
terial infection in infants and young children hospitalized with
respiratory syncytial virus lower respiratory tract infection,
Pediatr Infect Dis J 26 (2007), 311–315.
[19] B. Resch, W. Gusenleitner and W.D. Mueller, Risk of concur-
rent bacterial infection in preterm infants hospitalized due to
respiratory syncytial virus infection, Acta Paediatr 96 (2007),
495–498.
[20] G. Shazberg, S. Revel-Vilk, D. Shoseyov, A. Ben-Ami, A. Klar
and H. Hurvitz, The clinical course of bronchiolitis associated
with acute otitis media, Arch Dis Child 83 (2000), 317–319.
[21] K. Purcell and J. Fergie, Concurrent serious bacterial infec-
tions in 2396 infants and children hospitalized with respiratory
syncytial virus lower respiratory tract infections, Arch Pediatr
Adolesc Med 156 (2002), 322–324.
Copyright of Journal of Pediatric Infectious Diseases is the property of IOS Press and its content may not be
copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written
permission. However, users may print, download, or email articles for individual use.
